CN109963586B - 作为抗疟疾疫苗的生物融合蛋白 - Google Patents

作为抗疟疾疫苗的生物融合蛋白 Download PDF

Info

Publication number
CN109963586B
CN109963586B CN201780051251.4A CN201780051251A CN109963586B CN 109963586 B CN109963586 B CN 109963586B CN 201780051251 A CN201780051251 A CN 201780051251A CN 109963586 B CN109963586 B CN 109963586B
Authority
CN
China
Prior art keywords
glu
val
ile
lys
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780051251.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109963586A (zh
Inventor
皮埃尔·德吕耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vac4all Pte Ltd
Original Assignee
Vac4all Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vac4all Pte Ltd filed Critical Vac4all Pte Ltd
Publication of CN109963586A publication Critical patent/CN109963586A/zh
Application granted granted Critical
Publication of CN109963586B publication Critical patent/CN109963586B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201780051251.4A 2016-07-21 2017-07-21 作为抗疟疾疫苗的生物融合蛋白 Active CN109963586B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16180544 2016-07-21
EP16180544.5 2016-07-21
PCT/SG2017/050369 WO2018017020A1 (en) 2016-07-21 2017-07-21 Biofusion proteins as anti-malaria vaccines

Publications (2)

Publication Number Publication Date
CN109963586A CN109963586A (zh) 2019-07-02
CN109963586B true CN109963586B (zh) 2023-11-03

Family

ID=56550732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780051251.4A Active CN109963586B (zh) 2016-07-21 2017-07-21 作为抗疟疾疫苗的生物融合蛋白

Country Status (10)

Country Link
US (2) US20210038706A1 (enExample)
EP (2) EP3487526B1 (enExample)
JP (2) JP2019526274A (enExample)
KR (2) KR20190090775A (enExample)
CN (1) CN109963586B (enExample)
AU (1) AU2017300965B2 (enExample)
BR (1) BR112019001115A2 (enExample)
CA (1) CA3031399A1 (enExample)
TW (1) TWI780058B (enExample)
WO (1) WO2018017020A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3104833A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
WO2020104690A1 (en) * 2018-11-23 2020-05-28 Quine Medical Ab Bi-specific conjugates
WO2020217226A1 (en) 2019-04-25 2020-10-29 Dcprime B.V. Methods of tumor vaccination
NL2023863B1 (en) * 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof
CN111135290A (zh) * 2020-01-16 2020-05-12 定山石生物科技(北京)有限公司 一种用于激活人体免疫细胞的多肽试剂
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CA3203705A1 (en) 2021-01-22 2022-07-28 Erik Hans MANTING Methods of tumor vaccination
BE1029148B1 (fr) * 2021-02-26 2022-09-26 Curavac Europe Vaccin pour un traitement therapeutique ou prophylactique de la myastenie grave
CN118207228B (zh) * 2024-03-21 2025-03-14 中国科学院上海免疫与感染研究所 一种防治结合的多时期双靶点串联疟疾mRNA疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102807621A (zh) * 2011-06-01 2012-12-05 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
EP2460813A1 (en) * 2003-12-17 2012-06-06 Janssen Alzheimer Immunotherapy A beta immunogenic peptide carrier conjugates and methods of producing same
WO2014136064A2 (en) * 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102807621A (zh) * 2011-06-01 2012-12-05 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates;Feng Qian等;《Vaccine》;20070516;第25卷(第20期);参见第3923-3933页全文，尤其是摘要、第3924页左栏第2-3段、第3926页右栏第3段-第3929页右栏第1段 *

Also Published As

Publication number Publication date
KR20240154691A (ko) 2024-10-25
EP3487526B1 (en) 2022-07-06
BR112019001115A2 (pt) 2019-06-25
WO2018017020A1 (en) 2018-01-25
CA3031399A1 (en) 2018-01-25
JP2022116169A (ja) 2022-08-09
TWI780058B (zh) 2022-10-11
EP3487526A1 (en) 2019-05-29
US20210038706A1 (en) 2021-02-11
CN109963586A (zh) 2019-07-02
AU2017300965B2 (en) 2024-09-12
AU2017300965A1 (en) 2019-02-07
JP2019526274A (ja) 2019-09-19
KR20190090775A (ko) 2019-08-02
JP7579298B2 (ja) 2024-11-07
EP4147715A1 (en) 2023-03-15
US20220409712A1 (en) 2022-12-29
TW201803907A (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
CN109963586B (zh) 作为抗疟疾疫苗的生物融合蛋白
Drew et al. Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the: Taenia ovis 45W antigen
AU2011229518B2 (en) Tumor vaccination involving a humoral immune response against self-proteins
WO2009082440A2 (en) Compositions of toll-like receptor agonists and malaria antigens and methods of use
US20210101962A1 (en) Mosaic Chimeric Viral Vaccine Particle
JP4573773B2 (ja) マラリア・ワクチン
Bargieri et al. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium
AU603054B2 (en) Polypeptides comprising repeat units of plasmodium falciparum CS protein, and production thereof
CN100516219C (zh) 恶性疟原虫抗原多肽se36、其纯化方法、以及使用通过纯化得到的抗原的疫苗和诊断试剂
JP2000506381A (ja) マラリア原虫ｍｓｐ―１のｃ末端断片を含む組換えタンパク質
US12202865B2 (en) Multivalent malaria transmission-blocking vaccines
US7101556B2 (en) Preparation and usage of plasmodium fusion antigen
JPH0673097A (ja) マラリアワクチン
CN105367662B (zh) 一种hbv相关的融合蛋白、其制备方法及其应用
RU2341534C2 (ru) Иммуногенный гибридный полипептид против ожирения и вакцинная композиция на его основе
JPH11504215A (ja) 免疫原性の高められた修飾ポリペプチド
WO2013050034A1 (en) Production of a cysteine rich protein
Wang et al. Influence of glycosylphosphatidylinositol anchorage on the efficacy of DNA vaccines encoding Plasmodium yoelii merozoite surface protein 4/5
JPH0317099A (ja) マラリアワクチン
WO2024249116A1 (en) A multi-stage vaccine antigen for malaria
Ogun et al. The oligomerization domain of C4-binding protein acts as an adjuvant: a fusion protein of MSP119 with the murine C4bp domain protects mice against malaria.
Malaria Immunization of Mice with DNA-Based
JP2005021166A (ja) 抗原タンパク質及び該タンパク質をコードする核酸

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant